JP2001522858A5 - - Google Patents

Download PDF

Info

Publication number
JP2001522858A5
JP2001522858A5 JP2000520458A JP2000520458A JP2001522858A5 JP 2001522858 A5 JP2001522858 A5 JP 2001522858A5 JP 2000520458 A JP2000520458 A JP 2000520458A JP 2000520458 A JP2000520458 A JP 2000520458A JP 2001522858 A5 JP2001522858 A5 JP 2001522858A5
Authority
JP
Japan
Prior art keywords
minutes
merck
eluent
mixture
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000520458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001522858A (ja
Filing date
Publication date
Priority claimed from GBGB9723566.7A external-priority patent/GB9723566D0/en
Application filed filed Critical
Publication of JP2001522858A publication Critical patent/JP2001522858A/ja
Publication of JP2001522858A5 publication Critical patent/JP2001522858A5/ja
Pending legal-status Critical Current

Links

JP2000520458A 1997-11-08 1998-11-06 化合物 Pending JP2001522858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9723566.7A GB9723566D0 (en) 1997-11-08 1997-11-08 Chemical compounds
GB9723566.7 1997-11-08
PCT/EP1998/007022 WO1999024450A2 (en) 1997-11-08 1998-11-06 Adensine a1 receptor agonists

Publications (2)

Publication Number Publication Date
JP2001522858A JP2001522858A (ja) 2001-11-20
JP2001522858A5 true JP2001522858A5 (enExample) 2006-01-05

Family

ID=10821742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000520458A Pending JP2001522858A (ja) 1997-11-08 1998-11-06 化合物

Country Status (24)

Country Link
US (1) US6407076B1 (enExample)
EP (1) EP1027363B1 (enExample)
JP (1) JP2001522858A (enExample)
KR (1) KR20010031883A (enExample)
CN (1) CN1285842A (enExample)
AP (1) AP2000001803A0 (enExample)
AT (1) ATE242259T1 (enExample)
AU (1) AU1232799A (enExample)
BR (1) BR9813973A (enExample)
CA (1) CA2309199A1 (enExample)
DE (1) DE69815378T2 (enExample)
EA (1) EA200000393A1 (enExample)
EE (1) EE200000284A (enExample)
ES (1) ES2201552T3 (enExample)
GB (1) GB9723566D0 (enExample)
HR (1) HRP20000276A2 (enExample)
HU (1) HUP0004106A2 (enExample)
IL (1) IL135965A0 (enExample)
IS (1) IS5478A (enExample)
NO (1) NO20002360L (enExample)
PL (1) PL341091A1 (enExample)
SK (1) SK6712000A3 (enExample)
TR (1) TR200002157T2 (enExample)
WO (1) WO1999024450A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6784165B1 (en) 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
JP2004505048A (ja) * 2000-08-01 2004-02-19 ユニバーシティー　オブ　ヴァージニア　パテント　ファウンデーション 血管新生を処理するための、選択的アデノシンａ１受容体アゴニスト、アンタゴニストおよびアロステリックエンハンサーの使用
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
JP4514452B2 (ja) * 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2576826C (en) * 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EA025415B1 (ru) 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
KR20130028058A (ko) * 2010-02-03 2013-03-18 엠이에이치 어소시에이츠, 인코포레이티드 선택적 및 생활성 동배체로서의 다수 치환된 플루오로메탄류
EP2569325A4 (en) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp METHOD FOR REDUCING INNER EYE PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA), CPA DERIVATIVES OR PRODRUGS THEREOF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
AU2022597A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Similar Documents

Publication Publication Date Title
JP2001522858A5 (enExample)
JP2001522857A5 (enExample)
Stein et al. Phenylacetylglutamine as a constituent of normal human urine
Adam et al. Routine synthesis of L-[18F] 6-fluorodopa with fluorine-18 acetyl hypofluorite
JP2749272B2 (ja) アントラサイクリノングリコシドの精製法
WO2004048256A3 (en) Separation of carbon nanotubes dispersed by nucleic acids
RU2001118849A (ru) Очистка циклопептидных соединений эхинокандина
KR840008163A (ko) 항생물질 엘 17054의 제조방법 및 그 조성물
KR960022971A (ko) 들깨유로부터 α-리놀렌산(ALA)을 분리, 정제하는 방법
JP2003534349A (ja) （ｓｓ，ｒｓ）−ｓ−アデノシル−ｌ−メチオニンの薬剤として許容される塩の調製方法
McMahon et al. High-performance liquid chromatographic determination of taurine in human plasma using pre-column extraction and derivatization
US20050119346A1 (en) Process for the preparation of cilastatin
Hearn et al. High pressure liquid chromatography of thyromimetic iodoamino acids
Swiderski et al. Polystyrene reverse-phase ion-pair chromatography of chimeric ribozymes
CN113061152A (zh) 一种利用氨基型树脂分离纯化甘油葡萄糖苷的方法
JP3141029B2 (ja) ペントスタチンの精製方法
WO2001030796A1 (en) A process for preparing acarbose with high purity
JPH0399259A (ja) クロマトグラフ充填剤及びこれによる水溶性有機化合物の分離法
Sano et al. Optical resolution of thiol enantiomers by high-performance liquid chromatography using precolumn fluorescence derivatization with o-phthalaldehyde and α-amino acids
Yu et al. Enantiomeric separation of fluoxetine derivatives on polysaccharide‐based chiral columns
JP2002504855A (ja) グラディエント溶離法
WO2001014405A3 (en) Methods of obtaining 2-methoxyestradiol of high purity
Miyashita et al. Studies on Iodinated Compounds. I. Improved Procedure for Preparation of Monoiodohistidine
JP4070904B2 (ja) イオン化する化合物用の分離剤およびその製造方法
ARAKAWA et al. Improved Synthesis of Sulfoconjugate Isomers of Norepinephrine and Epinephrine, and Separation of All Sulfoconjugates of Catecholamines by Thin-Layer and High-Performance Liquid Chromatography